



Benefits of Low Dose 3D Imaging with EOS System Highlighted at the 2013 Scoliosis Research Society Conference

An EOS educational symposium gathers more than 60 spine surgeons

Paris, 24 September 2013 - EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced a strong visibility at the 48th annual conference of the Scoliosis Research Society (SRS) in Lyon, France that included the presentation of clinical data and a Company-hosted educational symposium for more than 60 spine surgeons from 15 countries.

The benefits of the EOS system in the treatment of adolescent scoliosis were highlighted in multiple scientific sessions related to imaging and associated irradiation, as well as to advances in spinal deformity treatment.

Alongside to the SRS meeting, EOS imaging hosted an educational symposium at the SRS conference titled "Pushing the boundaries of spine treatment with low dose images." The session featured presentations from five experts in advanced spinal treatments from the United States, Canada and France and was attended by more than 60 spine surgeons from around the world. Dr Suken Shah, from Nemours/Al duPont Hospital, chair of this symposium, said: "EOS brings to spinal pathologies the solution we surgeons have wanted: a low dose, full spine or full body exam that gives us a 3D understanding and, even more, very accurate measurements of the spinal deformity. The success of this symposium demonstrates that EOS is becoming a 'must have' in scoliosis treatment."

The Company enjoyed success outside of the SRS conference in Lyon this week with the installation of the city's third EOS system. The system was installed at the Centre Médico-Chirurgical de Réadaptation (CCMR) des Massues, La Croix Rouge (French Red Cross) hospital. CCMR specializes in orthopedic surgery and musculoskeletal rehabilitation for children, adolescents, adults and amputees.

Marie Meynadier, CEO of EOS imaging, said, "*The Scoliosis Research Society gathers the best surgeons who thrive worldwide to treat spinal deformity, whether on the very young (Early Onset Scoliosis), the adolescent (Adolescent Idiopathic Scoliosis) or on adults. This annual meeting has seen very prominent surgeons share their views and positive experience with the EOS system in front of their peers, including a growing number of users from North America, and confirms our technology adoption.*"

For further information about the Company or EOS®, the first full-body, low-dose 3D imaging system, please visit www.eos-imaging.com.

About the Scoliosis Research Society (SRS):

The Scoliosis Research Society is a non-profit, professional organization, made up of physicians and allied health personnel. Founded in 1966 with 35 members, the SRS has grown to include almost 1100 of the world's leading spine surgeons in 41 countries, as well as some researchers, physician assistants and orthotists who are involved in research and treatment of spinal deformities. The organization holds an annual meeting with strong global participation from spine surgeons and specialists from around the world. This annual scientific meeting includes scientific presentations related to spine surgery and spinal deformity, which are selected through a process of abstract submission and peer review. A second annual meeting, entitled International Meeting on Advanced Spine Techniques (IMAST) is held on emerging technologies and techniques.

**About EOS imaging:**

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of over 60 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore.

**EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI**

Next press release: revenue for the 3rd quarter of 2013 on 15 October 2013 (after market).

Contacts:**Anne Renevot
CFO**

Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.

Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91 – eosimaging@newcap.fr

The Ruth Group (US)

Press Relations
Melanie Sollid-Penton
Tel: 646-536-7023 – msollid@theruthgroup.com